SAG
MTNB icon

SageView Advisory Group’s Matinas BioPharma MTNB Stock Holding History

SageView Advisory Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed -$6 – 1754
2025
Q4 		$6 Buy
+10
New +$12 ﹤0.01% 2599

Other funds holding MTNB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

SageView Advisory Group's MTNB Position: Q1 2026 in Review

SageView Advisory Group sold out of Matinas BioPharma (MTNB) in Q1 2026, closing a stake of 10 shares — an estimated $6 sold.

SageView Advisory Group first reported a position in MTNB in Q4 2025 and held it in 1 quarter. The position peaked at $6 in Q4 2025. 28 funds tracked by Wall St. Rank hold MTNB as of Q1 2026.

  • SageView Advisory Group reported no remaining Matinas BioPharma position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 10 Matinas BioPharma shares in Q1 2026, an estimated $6.
  • SageView Advisory Group first reported a position in Matinas BioPharma in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Matinas BioPharma position peaked at $6 in Q4 2025.
  • 28 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.